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Tight control of storage and synthesis of glucose during nutritional transitions is essential to maintain blood glucose levels, a
process in which the liver has a central role. PPARα is the master regulator of lipid metabolism during fasting, but evidence is
emergingforaroleofPPARαinbalancingglucosehomeostasisaswell.ByusingPPARαligandsandPPARα−/− mice,severalcrucial
genes were shown to be regulated by PPARα in a direct or indirect way. We here review recent evidence that PPARα contributes to
the adaptation of hepatic carbohydrate metabolism during the fed-to-fasted or fasted-to-fed transition in rodents.
1.Introduction
1.1. PPARα. Peroxisome proliferator-activated receptor α
(PPARα)i san u c l e a rr e c e p t o ra n dm a s t e rr e g u l a t o ro f
lipid metabolism. In the liver of rodents, PPARα is an
important orchestrator of the switch from the fed to the
fasted condition via activation of fatty acid catabolism by
mitochondrial, microsomal, and peroxisomal β-oxidation in
order to maintain energy homeostasis during fasting and
to protect cells from lipid overload [1–4]. Fasting periods
are characterized by increased hepatic fatty acid inﬂux,
which bears similarities with high fat feeding. Moreover,
PPARα functions as a fatty acid sensor and mediates the
remodeling of hepatic lipid metabolism via the induction of
severalgenes,likefattyacidtransporters,fattyacidactivation
genes, and key enzymes of the fatty acid oxidation (FAO)
pathways [4]. Besides inducing FAO, PPARα also stimulates
the synthesis of ketone bodies from fatty acids [4], which in
the fasted state serve as fuel for many extrahepatic organs,
such as muscle [5]. In this way, fatty acids are preferentially
utilized as fuel in periods of fasting.
The transactivation potential of PPARα can be stim-
ulated either by PPARα ligands or by the presence
of high levels of the transcriptional coactivator peroxi-
some proliferator-activated receptor gamma coactivator-1α
(PGC-1α), as occurs during fasting [6]. Moreover, the
induction/suppression of PPARα target genes will also
depend on PPARα expression levels which are in part
autoregulated [6]. Since nonesteriﬁed fatty acids are known
ligands for PPARα, elevated plasma free fatty acids (FFAs)
could be expected to act as endogenous PPARα ligands
during fasting and to mediate the fasting-induced metabolic
eﬀects. Surprisingly, it was shown that this activation of
hepatic PPARα does not occur by plasma FFAs [6, 7], but by
fatty acids synthesized in hepatocytes de novo [7, 8]. Hepatic
PPARβ/δ rather than PPARα was shown to be responsive
to elevated fasting plasma FFAs levels [6]. Moreover, also
dietary fatty acids have been reported to be able to activate
PPARα [9–11].
Importantly, there are clear diﬀerences in PPARα biology
between mice and humans. It was long thought that in
comparison with mouse liver, human liver contains 10-fold
lower levels of PPARα mRNA [12], but recent investigations
indicated that both species contain comparable levels [13]
which may ﬂuctuate throughout the day and according to
feeding status. Although the induction of mitochondrial
FAO and lipid-lowering eﬀects are universal for PPARα
ligands, they do not induce peroxisome proliferation or
tumor development in the liver of species other than rodents
[14, 15]. Using primary mouse and human hepatocytes, it
was demonstrated that besides the common regulation of
lipid metabolism, PPARα ligands induce a divergent set of2 PPAR Research
genes in both species [13]. Notably, changes in carbohydrate
gene expression were only observed in mouse hepatocytes.
1.2. Hepatic Glucose Metabolism: From the Fed to the Fasted
State and Back. Tight control of blood glucose levels is
crucial, since a fall in blood glucose can cause metabolic
dysfunction, brain dysfunction, seizures, coma, and death.
A persistent elevation in blood glucose leads to glucose
toxicity, since hyperglycemia induces tissue damage through
mitochondrial superoxide production which contributes to
β-cell dysfunction and micro- and macrovascular compli-
cations of diabetes such as neuropathies and vasculopathies
[16, 17].
In order to protect blood glucose levels and depending
on the metabolic needs, hepatic carbohydrate metabolism
undergoes a shift from glucose storage via glucose uptake
and glycogen synthesis during feeding towards glucose
production via glycogenolysis and gluconeogenesis during
fasting. In this way, the liver plays a central role in the
adaptiveresponsetofasting.Duringtheﬁrsthoursoffasting,
glycemia is preserved by the process of glycogenolysis at
the expense of liver glycogen reservoirs. During prolonged
fasting, when glycogen stores become critically low, hepatic
g l u c o s ep r o d u c t i o ns h i f t st ode novo glucose synthesis
(gluconeogenesis) in order to maintain blood glucose levels.
These metabolic changes are reﬂected in the expression
and/or activity of hepatic enzymes. For example, prolonged
fasting induces a decrease of the maximal activity of the
glycolytic enzyme glucokinase and stimulates the expres-
sion of the gluconeogenic gene phosphoenolpyruvate car-
boxykinase (PEPCK).Simultaneously, thelipogenic enzymes
acetyl-coenzyme A carboxylase and fatty acid synthase are
suppressed and the activity of mitochondrial β-oxidation
is enhanced. As a consequence, the hepatic carbon ﬂux
is directed towards gluconeogenesis and glucose output
rather than glucose uptake and glycolysis, and towards FAO
and ketogenesis rather than de novo fatty acid synthesis.
During the ﬁrst few hours of refeeding after prolonged
fasting, this pattern of carbon ﬂux is maintained although
the gluconeogenic product glucose-6-phosphate (G6P) is
directed towards glycogen synthesis, while glucose output is
suppressed.
As already mentioned, PPARα is activated in liver after
transition from the fed to the fasted state. Although PPARα
hasmostlybeenconnectedwithfattyacidcatabolism,several
lines of evidence indicate that PPARα has an important
role in the control of glucose homeostasis as well. For a
start, fasting PPARα−/− mice display marked hypoglycemia
(see Section 3.1)[ 3, 7, 18–25]. Next, several enzymes
of carbohydrate metabolism were shown to be regulated
by PPARα (see Sections 2 and 3). Finally, PPARα was
proposed to have a role in inﬂuencing insulin sensitivity (see
Section 4). In this multitude of studies, often, contradictory
ﬁndings were published. These sometimes depended on the
experimental system used, but opposing results were also
obtained for comparable paradigms. Therefore, this paper
focusesonthelinksbetweenPPARαandglucosehomeostasis
in rodent liver and on the potential direct and indirect
mechanisms governing this regulation.
2. Role of PPARα in the Use of
Glucose-6-Phosphate
In the fed state, when blood glucose levels are high, glucose
is taken up by the liver and rapidly phosphorylated to G6P
by glucokinase. G6P is at the crossroads of 4 pathways: it
c a nb eb r o k e nd o w nv i ag l y c o l y s i st o w a r d sp y r u v a t e ,s t o r e d
as glycogen, dephosphorylated to glucose, or used in the
oxidative arm of the pentose phosphate pathway (PPP)
(Figure 1).
2.1. Role of PPARα in Regulating Glycolysis. Because PPARα
coordinates the fasting response in liver, it can be questioned
whether it also contributes to the suppression of glycolysis.
Glycolysis serves only as a small generator of ATP whereas
it is the principal supplier of pyruvate, which can be further
metabolized. Important players in glycolysis are transporters
for glucose entry, glucokinase, and the key glycolytic
enzymes phosphofructokinase (PFK) and pyruvate kinase
(PK) (Figure 2). Hepatic glucokinase expression levels and
glycolyticﬂuxaremainlyregulatedinresponsetothefeeding
status. Glucokinase transcription is induced by insulin via
sterol regulatory element-binding protein 1c (SREBP-1c)
a n dr e p r e s s e db yg l u c a g o n[ 26]. The rate-limiting enzyme
PFK is also regulated by insulin [27]. Hepatic expression
of PK [28] is tuned independently of insulin, via glucose
signaling, which involves binding of carbohydrate response
element binding protein to the promoter. The postglycolytic
fate of pyruvate is determined by pyruvate dehydrogenase
kinase 4 (PDK4), which phosphorylates and inactivates
pyruvate dehydrogenase (PDH), the mitochondrial enzyme
needed to convert pyruvate to acetyl-coenzyme A (acetyl-
CoA) (Figure 2). The latter can enter the tricarboxylic acid
(TCA) cycle for energy production but can also be used
to build fatty acids for energy storage (Figure 1). When
PDH is inactive, pyruvate cannot enter the mitochondria
and will be metabolized to lactate, in order to regain NAD+
units. Transcription of PDK4 is stimulated by PPARα and
glucocorticoids during fasting and is suppressed by insulin
[29].
Administration of the PPARα ligand fenoﬁbrate to mice
caused decreased expression levels of glucokinase as well as a
decreased ﬂux through this enzyme, indicative of lower hep-
aticglucoseuptake[30].DecreasedtranscriptsofPK[30–33]
and decreased glucokinase activity [31] after administration
of an exogenous PPARαligand,suggestedthatPPARαindeed
controls the glycolytic pathway (Figure 2). In contrast, in
other studies, glucokinase expression was not aﬀected by
feeding mice the PPARα activator WY14643 [7]. The rat
glucokinase promoter contains a functional PPAR response
element (PPRE) [34], which was shown to be activated both
by LXRα/RXRα and PPARγ/RXRα in a luciferase reporter
assay [26]. Interaction of this PPRE with PPARα,h o w e v e r ,
was not studied so far.
WY14643 reduced basal and glucose-stimulated PK
expression in primary hepatocytes [33]. In line with these
ﬁndings, cloﬁbrate or WY14643 treatment of rats also
strongly reduced PK expression [31–33] whereas this sup-
pression did not occur in PPARα−/− mice [32]. A directPPAR Research 3
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Figure 1: Inﬂuence of insulin and PPARα on carbohydrate metabolic pathways. Diﬀerent fates and diﬀerent sources of hepatic G6P are
depicted, together with the regulatory eﬀects of PPARα. FA: fatty acids; FAO: fatty acid oxidation; G6P: glucose-6-phosphate; OXPHOS:
oxidative phosphorylation; TCA: tricyclic acid cycle.
interaction of PPARα with the PK promoter could not
be proven [32], and hence suppression of gene expression
must involve some intermediary factors. It was proposed
that ligand-activated PPARα interferes with coactivator
recruitment and decreases histone H4 acetylation of PK
[33]. In conﬂict with these observations showing suppressed
glycolytic enzymes by PPARα activators, a decreased expres-
sion of glucokinase and pyruvate kinase was reported in
PPARα−/− mice both in fasted and in fed conditions [20, 35].
It is not clear why both after PPARα activation and
PPARα depletion glycolytic enzyme levels are suppressed.
In fact, both the long-term deletion of this transcription
factor, which might install a new metabolic homeostasis,
as the long-term activation of PPARα using synthetic high
aﬃnity agonists, are nonphysiological conditions and the
resultshavetobeinterpretedwithcare.Refeedingisexpected
to induce glycolytic enzymes in response to insulin signaling.
This was not the case in PPARα deﬁcient mice, possibly
indicating that PPARα−/− hepatocytes are insulin resistant
(see also below).
Not only will activated PPARα reduce the amounts of
pyruvateformed,butitwillalsopowerfullypreventtheentry
of pyruvate into the mitochondrial TCA cycle by strongly
inducing the expression of PDK4 [36, 37]. Because PPARα
simultaneously stimulates β-oxidation, it privileges FAO to
provide acetyl-CoA for the generation of energy via the
TCA cycle and oxidative phosphorylation (OXPHOS). As a
result, pyruvate will be available for gluconeogenesis, which
implies a role for PPARα in gluconeogenic regulation. Two
PPREs have been identiﬁed in the promoter of PDK4 [38].
Although PDK4 expression robustly increases in response to
PPARα activators and fasting, PPARα/RXRα did not bind
these PPREs with high aﬃnity in a gel-shift assay [38].
Earlier, it was already proposed that PDK4 is inﬂuenced
by PPARα indirectly [39]. Because the coactivator PGC-
1α is able to bind and activate the PDK4 promoter, it is
believed to be involved in the upregulation of PDK4 in
response to fasting [40]. The essential role of PPARα in
the induction of PDK4 upon fasting was also conﬁrmed
by the absence of this response in PPARα knockout mice
[39]. Furthermore, in wild-type mice, PDK4 levels were
normalized after 6 hours refeeding following a period of
fasting,whichcausedsuppressionofgluconeogenicratesand
stimulation of glycolysis and lipogenesis. This response was
b l u n t e da sw e l li nP P A R α−/− mice [39].
Summarizing, during the fed-to-fasted transition,
PPARα induces and orchestrates a switch from glucose to
fatty acid utilization for energy production in hepatocytes.4 PPAR Research
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Simultaneous with the activation of FAO by PPARα,
glycolysis is inhibited. PPARα activation reduces PK
expression and induces PDK4 (Figure 2). So far, however,
no direct interaction of PPARα with the promoters of these
genes was demonstrated.
2.2. Role of PPARα in Regulating the Pentose Phosphate
Pathway. Interestingly, it was suggested that the ﬂux through
the PPP was increased after fenoﬁbrate treatment [30].
Indeed, expression levels of 6-phosphogluconate dehydro-
genase (6PDGH), the rate-limiting enzyme of the oxidative
branch of the PPP, and transaldolase 1 (Taldo1), a key
enzyme for regulating ﬂux from the triose phosphate pool
through the nonoxidative limb of the pentose cycle, were
augmented in fenoﬁbrate treated mice [30] (Figure 2). This
was in line with reduced levels of several PPP enzymes in
PPARα−/− mice [35]. Furthermore, the reduced content of
G6P in fenoﬁbrate-treated mice is diﬃcult to reconcile with
an increased ﬂux through gluconeogenesis (see below) and
with reduced glycolysis (see above). Therefore, the hypoth-
esis of increased rates of glucose oxidation through PPP is
attractive. PPP remodeling of hepatic glucose metabolismPPAR Research 5
upon PPARα activation may be important to provide
NADPH needed to maintain the lipogenic ﬂux, but may
also support antioxidant action, since PPP is coupled to the
synthesis of reduced gluthatione [41].
2.3. Role of PPARα in Glycogen Homeostasis. When nutrient
supply is abundant, excess glucose is stored as glycogen in
liver and muscle. While skeletal muscle glycogen mainly
serves to fuel muscle contractions, hepatic glycogen stores
are used to keep blood glucose levels up to the mark between
meals.
Glycogen synthase 2 (Gys-2) is the rate-limiting enzyme
in the synthesis of glycogen in liver (Figure 3). The activity of
Gys-2 is inhibited via phosphorylation by glycogen synthase
kinase 3β (GSK-3β). In turn, GSK-3β kinase activity is
attenuated after phosphorylation by Akt. Glycogen storage
in liver is controlled by many factors, of which the rate of
portal venous glucose delivery to the liver and insulin levels
are best known. Insulin stimulates glycogen synthesis via
Akt-mediated phosphorylation of GSK-3β, while glucagon
inhibits Gys-2 activity through cAMP-mediated activation
of GSK-3β. In periods of food deprivation, hepatic glycogen
is broken down in order to maintain euglycemia. Glyco-
gen phosphorylase (GP), the key enzyme responsible for
glycogenolysis, generates glucose-1-phosphate, which is con-
verted to G6P by phosphoglucomutase (Figure 3). Glucose-
6-phosphatase (G6Pase), which catalyzes the conversion to
glucose, is the rate-limiting enzyme in the regulation of
blood glucose levels by breakdown of glycogen. The activity
of GP is mainly inhibited by the presence of high levels of
glucose.
Remarkably, during the ﬁrst hours of fasting, when
PPARα levels increase, hepatic Gys-2 expression and activity
are induced simultaneously with the active breakdown of
glycogen stores [21, 42–44]. It was suggested that this may
serve to prime the glycogen synthesizing system to rapidly
replenish stores when dietary glucose becomes available
again [44].
Gys-2 was identiﬁed to be a PPARα target gene since
PPARα ligands induced Gys-2 expression in rat and mouse
primary hepatocytes but not in PPARα−/− hepatocytes [44].
Two putative PPREs were identiﬁed in the mouse Gys-
2 gene. Based on chromatin immunoprecipitation (ChIP)
analysis, gel-shift experiments and luciferase reporter assays,
the direct repeat 1 (DR1) in intron 1 (DR1int) was shown
to be the response element for PPARs and the DR1 in
the upstream promoter (DR1prom) the response element
for hepatocyte nuclear factor 4 alpha (HNF4α). In liver,
which expresses high amounts of HNF4α,D R 1 p r o mi s
occupied and activated by HNF4α,b u tn o tb yP P A R α, while
DR1int is bound by PPARα and not by HNF4α [44]. It
was suggested that during fasting, when hepatic PPARα
levels increase, competition between these two transcription
factors may take place at the level of binding to common
co-activator proteins [44]. Taken together, these in vitro
observations indicate that besides HNF4α,P P A R α activation
might promote Gys-2 expression. For GP, the key enzyme
of glycogen breakdown, there are no in vitro studies on
regulation by PPARα so far.
A number of studies were conducted in which PPARα
agonists were administered to rodents after which glycogen
content, glycogen metabolizing enzyme expression, and/or
ﬂuxes were monitored. In all cases, a reduction of hepatic
glycogen storage was seen but the proposed underlying
mechanisms are rather contradictory. In mice maintained
on a diet containing ciproﬁbrate or fenoﬁbrate, lower
hepatic glycogen stores [25, 30] were accompanied by lower
hepatic G6P content [30], which is both the precursor
in glycogen synthesis and the end product of glycogen
breakdown. According to Oosterveer et al., there was both
an increased ﬂux of glycogen synthesis through Gys-2 and
an increased ﬂux of glycogen breakdown through GP [30].
In contrast, cloﬁbrate treatment of rats reduced both Gys-
2 and GP activity, resulting in reduced hepatic glycogen
content, however, without altering hepatic G6P levels [31].
In yet another study, treatment of rats with WY14643 did
not alter Gys-2 expression, but did decrease GP expression
levels [45]. Unfortunately, in none of these studies Gys-2
expression, glycogen levels, and glycogenic ﬂux were studied
simultaneously in the same model.
The ﬁndings in PPARα knockout mice make the picture
even more confusing. Fasted PPARα−/− mice suﬀer from
severe hypoglycemia starting already several hours after food
withdrawal [3, 23]. During the ﬁrst hours of fasting, blood
glucose levels are mostly maintained by hepatic glycogenol-
ysis. The steeper drop in blood glucose in PPARα−/− mice
duringearlyfasting,therefore,mayreﬂectareducedglycogen
reserve or impaired liberation of glucose. Several groups
reported that in the fed state hepatic glycogen stores were
lower in PPARα−/− mice [3, 20, 21] compared to control
mice, but no diﬀerence was observed in the fasted state
[3,20].Ontheotherhand,astudyperformedbyBandsmaet
al. [21] showed a reduced depletion of glycogen upon fasting
(15h or 24h) concomitant with lower GP levels. According
to several other groups, both hepatic glycogen storage in
the fed state [25, 39] and glycogen depletion in response to
fasting [20, 25, 39]w e r eu n a ﬀected in PPARα−/− mice. It
is not clear why opposing results were obtained by diﬀerent
investigators using the same mouse model.
More consistent results were obtained in studies where
a prolonged period of fasting was followed by refeeding.
Repletion of glycogen stores via hepatic glycogen synthesis
was consistently impaired by PPARα deﬁciency in all studies
[20, 39, 44], despite normal insulin and glucose levels after
refeeding [39]. It was proposed to be the consequence of
reduced FAO and subsequently reduced gluconeogenesis
and glycogen synthesis due to hampered production of
substrates [39]. In the absence of PPARα, expression of Gys-
2 was markedly reduced during refeeding after prolonged
fasting[44],likelyexplaining thediminished rateofglycogen
formation upon refeeding in PPARα−/− mice.
Notably, despite reduced Gys-2 levels, gluconeogenic
ﬂ u xi nf a s t e dP P A R α−/− mice was directed more towards
glycogen, than towards blood glucose output [21]. However,
no explanation was given for this discrepancy. Expres-
sion of GP was suppressed in fasted PPARα−/− mice,
but regrettably, the ﬂux through GP was not studied
[21].6 PPAR Research
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A p a r tf r o mad i r e c te ﬀect on glycogen metabolizing
enzymes, PPARα may indirectly aﬀect the fate of newly
formed G6P which is either used in glycolysis, for transfer
to plasma as glucose, for glycogen synthesis or to enter the
PPP pathway (Figure 1). Normally, insulin directs newly
formed G6P towards glycogen disposition. According to
Sugden et al., PPARα deﬁciency resulted in impaired insulin
action (see also below) with respect to net hepatic glycogen
disposition starting from G6P on refeeding after starvation
[39],resultinginslowerrepletionofglycogenstores.Insharp
contrast, as mentioned above, it was shown by performing
ﬂux studies with stable isotopes that newly synthesized
G6P was partitioned away from plasma glucose towards
glycogen synthesis in PPARα knockout mice [21]. These two
l i n e so fo b s e r v a t i o n sa r em u t u a l l ye x c l u s i v e .H o w e v e r ,t h e
observation of reduced glycogen repletion upon refeeding
and reduced Gys-2 expression levels in PPARα−/− mice
is consistent between the diﬀerent studies, pointing to an
important role of PPARα in the control of glycogen synthesis
(Figure 3).
3.Gluconeogenesis
After prolonged fasting, blood glucose for consumption
by the brain, the kidney medulla, and red blood cells is
exclusively maintained by gluconeogenesis that primarily
takes place in hepatocytes. The main precursors for hepatic
gluconeogenesis are pyruvate, lactate, amino acids, and
glycerol (derived from the backbone of triglycerides), which
are converted to glucose via a series of reactions in the
cytosol and mitochondria (Figure 2). After depletion of
carbohydrate reserves, triacylglycerol stores are mobilized
from adipose tissue, increasing FFAs and glycerol concentra-
tion in plasma. These fatty acids are taken up by the liver,
where they can be stored or metabolized via β-oxidation
to produce acetyl-CoA. In turn, acetyl-CoA can be further
metabolized in mitochondria via the TCA cycle followed
by OXPHOS or it can be converted to pyruvate. Glycerol,
pyruvate, and ATP are then used in hepatic gluconeogenesis.
The main portion of lactate is produced in a process
known as the Cori cycle, in which lactate produced by
glycolysis in exercising muscle is shuttled to the liver where
it is converted back into glucose. Also in adipose tissue,
glucose is metabolized to lactate, which can subsequently be
transported to the liver. Alternatively, pyruvate produced in
muscle by glycolytic oxidation of glucose can be converted
to alanine via transamination (see Section 3.4). Alanine is
exported from muscle tissue to liver, where it is reconverted
to pyruvate and subsequently used in gluconeogenesis to
produce glucose. The latter can be transported back to
muscle in the glucose-alanine cycle.
Crucial steps in gluconeogenesis are the conversion of
pyruvate to oxaloacetate catalyzed by pyruvate carboxylase
(PC); the conversion of oxaloacetate to phosphoenolpyru-
vate catalyzed by PEPCK; the rate-limiting step catalyzed
by fructose-1,6-bisphosphatase (FBP) (Figure 2). The ﬁnal
step, hydrolysis of G6P to glucose by G6Pase, is shared
with the glycogenolytic pathway. PGC-1α is an important
transcriptional coactivator in the control of gluconeogenic
genes and it is strongly induced in the liver of fasting mice.
Glucagon, glucocorticoids, and adrenaline induce hepatic
glucose output during starvation via increasing PGC-1α
levels and activating gluconeogenesis. The concentration
of gluconeogenic substrates will also determine glucosePPAR Research 7
production. During the fasted-to-fed transition, insulin
suppresses PGC-1α mRNA levels and subsequently reduces
gluconeogenic rates and glucose output.
Given the important role of PPARα in the adaptive
response to fasting, it is conceivable that activated PPARα
directly regulates or indirectly inﬂuences the expression or
activity of some key gluconeogenic genes. Several in vitro
studies have been conducted to test whether gluconeogenic
genes such as PEPCK, G6Pase, and cytosolic glycerol 3-
phosphate dehydrogenase (cGPDH) are potential PPARα
targetgenes.Afterdiscussionofthehypoglycemicphenotype
of PPARα−/− mice, the general gluconeogenic pathway and
gluconeogenesis from the major substrates lactate/pyruvate
will be reviewed, whereafter glucose synthesis from the
minor substrates glycerol and alanine are discussed.
3.1. PPARα−/− Mice Are Hypoglycemic. It has been reported
repeatedly that although the general appearance of
PPARα−/− mice is normal in the fed state [18, 19, 21, 23],
they develop severe hypoglycemia during fasting [3, 7, 18–
25, 35]. However, discrepancies with regard to time of
onset of hypoglycemia and plasma insulin levels have been
published. Hypoglycemia occurred already after a few hours
of fasting according to some investigators [3, 23]w h e r e a s
in other studies, normal blood glucose levels were observed
after a 15-hour [21] or even 24-hour fasting period [39].
Sometimes, hypoglycemia was accompanied by increased
plasmainsulinconcentrationsascomparedtowildtypemice
[7, 23]. In other studies, PPARα−/− mice had lower blood
glucose values but unaltered insulin levels in comparison
with wild type mice [20, 21]. It was even reported that
steady-state fasting glucose levels were normal, while fasting
plasma insulin concentrations were increased in PPARα−/−
mice [39]. It is not resolved why opposing results were
obtained when studying the same knockout mice.
Severaldiﬀerentmechanismswereputforwardtoexplain
the fasting-induced hypoglycemia in PPARα−/− mice, some
of which may be operative simultaneously. Some researchers
believe this is mainly due to hepatic defects including
liver glycogen depletion [3, 18], a blunted gluconeogenic
response [18–20, 22, 24], reduced FAO rates [3, 18, 20, 25]
and/or stronger inhibition of hepatic glucose output due to
partitioning of G6P away from blood glucose [21]. Others
blame increased glucose utilization in extrahepatic tissues
[3, 20, 23, 35]. In favour of the last option is the fact that
hepatic reexpression of PPARα did not rescue the metabolic
phenotype of PPARα−/− mice [23].
3.2. Gluconeogenesis from Lactate/Pyruvate. When lactate is
used as a precursor of de novo glucose synthesis, it ﬁrst
has to be converted to pyruvate by lactate dehydrogenase
(LDH). Subsequently, PC, which is localized in mitochon-
dria, catalyzes the conversion of pyruvate to oxaloacetate,
which is a substrate for PEPCK, one of the key enzymes in
gluconeogenesis (Figure 2).
PPARα was shown to activate PEPCK promoter activ-
ity in Hepa1c1c7 cells [46], and in isolated rat hepato-
cytes, PEPCK and G6Pase expression increased in response
to palmitate [47]. The PEPCK promoter contains 2
intermediate-aﬃnity PPREs [48]. These PPREs were respon-
sible for the upregulation of PEPCK by PPARγ in adipocytes
[49], but direct interaction with PPARα was not studied.
ChIP experiments showed that upon palmitate treatment,
PPARα was recruited to the G6Pase promoter together with
HNF4α and several other transcription factors [47]. Sites of
interaction with the G6Pase promoter region or functional
studies, however, were not reported. No PPRE has been
identiﬁed in the promoter of LDH or PC [4].
When rodents were treated with PPARα ligands, the
eﬀects on gluconeogenesis were rather variable. In rats,
G6Pase activity was not aﬀected [31] whereas PEPCK
expression levels were reduced [50] and LDHb levels were
increased [45]. WY14643 feeding of mice had no eﬀect on
PC, PEPCK or G6Pase expression levels [7]. In a more
informative study, mice were treated with fenoﬁbrate and
not only expression levels of individual enzymes but also
gluconeogenicﬂuxwasanalysed[30].Thisﬂuxwasincreased
which was mirrored by increased expression of glycerol
kinase (see also Section 3.3), but expression of PGC-1α,
PEPCK and G6Pase was unaltered [30]. Interestingly, the
induction of the gluconeogenic genes PEPCK and G6Pase
by the glucocorticoid dexamethasone was shown to be
PPARα-dependent both in mice as well as in isolated human
hepatocytes[51].Lactate,beingthedominantgluconeogenic
precursor, and which is mainly derived from the Cori cycle,
is transported into hepatocytes via the monocarboxylate
transporter (MCT). Hepatic MCT-1 expression was shown
to be upregulated by fasting, WY14643, fenoﬁbrate and
dietary PPARα agonists in mice and rats [52, 53], resulting
in increased supply of gluconeogenic substrates.
Transcript levels of key gluconeogenic enzymes were
not uniformly altered in PPARα knockout mice. PEPCK
expression levels were shown to be similarly induced upon
fasting in wild-type and PPARα−/− mice [3, 22], which
suggests that PEPCK is upregulated by fasting in a PPARα
independent manner. Yet, lower expression of PEPCK in
24 hours fasted [21]a n dr e f e d[ 20]P P A R α−/− mice in
comparison with control animals was reported as well.
G6Pase and G6P translocase were not diﬀerently expressed
between fed PPARα−/− and wild type mice, but induc-
tion upon fasting of these two enzymes was impaired in
PPARα−/− mice [21]. Furthermore, a severe decrease in
expression of LDH and PC was found in PPARα−/− mice [4,
35], which suggests impaired gluconeogenesis from lactate.
However, most groups reported normal plasma lactate levels
in PPARα−/− mice [20, 21, 25]. This suggests a supportive
role for PPARα in the gluconeogenic response to fasting
(Figure 2).
More important than expression levels of gluconeogenic
enzymes is the capacity to produce glucose. In a study
with isolated hepatocytes from PPARα−/− mice, glucose
production from pyruvate was not signiﬁcantly altered [23],
but this was contradicted by Le May et al. who found a
20% reduction in gluconeogenesis from lactate/pyruvate in
PPARα−/− hepatocytes [24]. The rate of de novo synthesized
G6P and hepatic G6P levels were not diﬀerent in 15 hours
fasted PPARα−/− mice as compared with wild type mice
[21]. However, the rate of G6P towards plasma glucose8 PPAR Research
was diminished, while synthesis of uridine diphosphate
glucose (UDP-glucose), and thus glycogen formation was
higher [21], which could contribute to fasting hypoglycemia.
This was in line with decreased hepatic glucose production
(HGP) in fasted PPARα−/− mice [22]. The regulation of
HGP from pyruvate/lactate in PPARα−/− mice during the
physiologic situation of a moderate overnight fast (17 hours)
andrefeeding(5hours)wasstudiedmoreindetailusing 13C-
mass isotopomer distribution analysis (MIDA) by Xu et al.
[20]. In PPARα−/− mice, decreased HGP from lactate was
observed in the fed as well as in the fasted state [20].
Most studies mainly observed metabolic alterations in
PPARα−/− mice in starved conditions [3, 18–24], whereas
fed PPARα−/− mice had normal blood glucose [18, 19, 21,
23]. In a study performed by Atherton et al., however,
metabolic alterations were also observed in fed PPARα−/−
mice [54]. Here, metabolic proﬁling of several PPARα−/−
tissues was performed via 1H-NMR spectroscopy and MS.
Important metabolic diﬀerences were detected in all tis-
sues, but in particular in liver. Liver of PPARα−/− mice
contained profoundly decreased levels of glucose, several
amino acids including glutamine and alanine, and increased
levels of lactate. The combined presence of lower glucose
and higher lactate content conﬁrms impaired gluconeoge-
nesis from lactate in PPARα−/− mice. This demonstrates
that a failure to express PPARα results in perturbed bal-
ance between glycolysis, TCA cycle and gluconeogenesis
[54].
Since the fasted PPARα−/− liver fails to induce fatty
acid β-oxidation, ketone body synthesis is hampered and
peripheral organs cannot be fueled with ketone bodies [3,
18, 19, 21, 25, 39]. Therefore, these organs solely rely on
glycolytic consumption of glucose and increased amounts of
lactate arise. However, since expression of key gluconeogenic
genes and HGP are not increased in PPARα−/− mice
compared with control mice [3, 20, 22, 35], this suggests
that the PPARα−/− liver does not upregulate gluconeogenesis
via compensatory mechanisms despite decreased systemic
glucose levels and increased peripheral production of the
gluconeogenic substrate lactate.
3.3. Gluconeogenesis from Glycerol. Cellular uptake of glyc-
erol is mediated by the transporters aquaporin 3 and
9 (AQP3 and AQP9). When glycerol is used as gluco-
neogenic precursor, this is ﬁrst phosphorylated to glycerol
3-phosphate via the action of glycerol kinase. This in turn
is converted to the gluconeogenic intermediate dihydroxy-
acetone phosphate via cytosolic (cGDPH) or mitochondrial
glycerol 3-phosphate dehydrogenase (mGDPH) (Figure 2).
The promoter of cGPDH was shown to contain a
functional PPRE by promoter deletion studies and was
functionally identiﬁed to be a direct target of PPARα by
transactivation, gel shift and ChIP experiments [22].
Treatment of mice with fenoﬁbrate resulted in increased
expression of glycerol kinase [30]. Fasting as well as
treatment with WY14643 induced an upregulation of the
expressionofgenesinvolvedinhepaticgluconeogenesisfrom
glycerol, including AQP3, AQP9, cGDPH, mGDPH, and
glycerol kinase [22], which was dependent on the presence
of PPARα (Figure 2). In line with the upregulation of
glycerol utilization genes via PPARα, WY14643 signiﬁcantly
decreased plasma glycerol levels in wild type but not in
PPARα−/− mice [22]. This decrease in plasma glycerol levels
was also observed in human atherosclerotic patients treated
with fenoﬁbrate for 4 weeks [22].
In accordance, decreased HGP from glycerol was
observed in fasted PPARα−/− mice [22]. However, opposite
ﬁndings were reported by Xu et al. [20], including enhanced
glycerol production, enhanced HGP from glycerol, and
enhanced total HGP in 17-hour fasted PPARα−/− mice,
which was suggested to occur as a compensating mechanism
for the decreased HGP from lactate.
Depending on the nutritional status, the importance
of glycerol as gluconeogenic precursor varies from 5%
postprandial in humans to being the main gluconeogenic
precursor after prolonged starvation in rodents [22]. Inas-
much as the conversion of glycerol to glucose in liver is
impaired in PPARα−/− mice, defective synthesis of glucose
from glycerol may partly explain the fasting-induced hypo-
glycemia in PPARα−/− mice. In conclusion, the metabolic
fate of glycerol is under the control of PPARα,w h i c h
stimulates its conversion to glucose in liver (Figure 2).
3.4. Gluconeogenesis from Alanine. During fasting, one of
the mechanisms for the synthesis of glucose involves protein
degradation, followed by the production and export of
alanine from muscle tissue to liver. Alanine is metabolized
by deamination and gluconeogenesis in the liver in the
glucose-alanine cycle [55]. Since hepatic levels of alanine
were lower in PPARα−/− mice, it was suggested that the
enzymes controlling this cycle may be constitutively more
activeinPPARα−/− mice[54].ItshouldbenotedthatPPARα
has a more general suppressive eﬀect on the trans- and
deamination of amino acids in rodents [56].
3.5. Gluconeogenesis—Conclusion. Upon activation of
PPARα, FAO is stimulated and increased amounts of acetyl-
CoA are produced. Further metabolism via TCA cycle and
OXPHOS provides the liver with intermediates and energy
for gluconeogenesis in order maintain fasting euglycemia.
PPARα receptor function regulates the rate and route of
HGP in the fasted state by controlling the ﬂux of lactate and
glycerol to glucose (Figure 2). Although not all studies are in
agreement, a dual block in the early steps of the conversion
of lactate to glucose and glycerol to glucose in PPARα−/−
micecausesamaladaptationtofastingandmayatleastpartly
explain the development of hypoglycemia in these mice.
cGPDH is the only gluconeogenic gene which was
identiﬁed to be a direct PPARα target gene. Although
PPARα plays a role in fasting-induced stimulation of glu-
coneogenic gene expression, this may occur via supporting
glucocorticoid action rather than direct stimulation of gene
transcription.
4. PPARα andHepatic InsulinSensitivity
Wholebodyinsulinsensitivityistheresultofbothperipheral
and hepatic insulin action [35]. Peripheral action of insulinPPAR Research 9
aﬀects tissue glucose uptake, and therefore glucose clearance.
In liver, insulin aﬀects the net balance of gluconeogenic
versus glycolytic ﬂux by inﬂuencing gene expression lev-
els.
It was shown that PPARα has an important modula-
tory function on hepatic insulin action through its target
TRB3, the mammalian tribbles homolog. During fasting and
upon WY14643 treatment, hepatic expression of TRB3 was
induced in wild type, but not in PPARα−/− mice [57]. TRB3
disrupts insulin signaling by interfering with activation of
Akt [58]. The PPARα-mediated induction of TRB3 was pro-
posed to suppress insulin action, to induce insulin resistance,
and subsequently to promote gluconeogenesis [57].
Based on these ﬁndings, it was expected that in the
absence of PPARα, insulin sensitivity would be increased.
However, in sharp contrast, hepatic insulin resistance was
observed in PPARα−/− mice.
Insulin action is of particular importance in liver during
the fasted-to-fed transition. Insulin then stimulates glycogen
repletion, glycolysis, and hepatic lipogenesis and suppresses
hepatic PDK4 protein expression and HGP. In PPARα−/−
mice, it was observed that all these insulin actions were
impaired, and therefore these mice were denoted as insulin
resistant [20, 35, 39, 44]. For example, diﬀerential expression
between the fasted and fed state of several insulin-responsive
genes was lost in PPARα−/− mice [35]. Both in the fed
and fasted state, G6P dehydrogenase (G6PDH) and Taldo
expression levels were lower in PPARα−/− mice and during
refeeding, induction of glucokinase expression was blunted
[35].BecauseSREBP-1cis a major mediator of insulin action
on hepatic glycolytic and lipogenic gene expression [59],
lower SREBP-1c expression levels in liver of PPARα−/− mice
also point to reduced hepatic insulin sensitivity.
Summarizing, during the fasted state, PPARα may have
a stimulatory role on gluconeogenesis not only via direct
gene induction or supporting glucocorticoid action (see Sec-
tion 3.2), but also through impairment of insulin signaling,
by inducing TRB3.
On the other hand, PPARα deﬁciency severely reduced
the responsiveness to insulin during the fasted to fed
transition in terms of gluconeogenic, glycolytic, and
lipogenic enzyme expression. The mechanism of this hepatic
insulin resistance in PPARα knockout mice was not resolved,
but it is likely not related to TRB3 and rather caused by fatty
acid accumulation as a result of impaired FAO.
5.Glucose as PPARαActivator
Besides the previously discussed modulatory role of PPARα
on carbohydrate pathways in liver, recently, a new and direct
link between PPARα and glucose has been proposed.
Hostetler et al. [60] showed that both glucose and its
metabolites glucose-1-phosphate and G6P are endogenous
ligands of PPARα with glucose having the highest aﬃnity,
well within the range of normal physiological levels. These
metabolites are supposed to interact directly with speciﬁc
amino acid residues in the PPARα ligand binding domain
[60],resultinginalteredPPARαsecondarystructure[60,61].
Afterglucosebinding,coactivatorrecruitment,DNAbinding
and transactivation potential of PPARα/RXRα heterodimers
were increased [60], but only in the presence of activating
PPARα ligands such as arachidonic acid or cloﬁbrate. In
the absence of other ligands, glucose inhibited recruitment
of coactivators and therefore suppressed PPARα regulated
transcription [60].
The impact of this direct interaction of glucose with
PPARα on the regulation of carbohydrate metabolism in
physiological conditions remains to be proven. Notably, in
thefastedstate,whenPPARαisactivated,hepaticglucoselev-
els are expected to be rather low. It also remains unexpected
that a hydrophilic ligand can aﬀect a hydrophobic binding
pocket. Therefore, these data await conﬁrmation and need to
be considered with care.
6. Concluding Remarks
From the above, it appears that hepatic PPARα plays an
important role in carbohydrate handling in rodent liver
by regulating expression of genes in a direct or indirect
way. During the fed to fasting transition, PPARα activation
contributes to the inhibition of glycolysis and to the induc-
tion of gluconeogenesis. However, since only a few genes
were shown to be directly targeted by PPARα, these eﬀects
are mostly governed by indirect mechanisms that remain
to be clariﬁed. Together with its well-known stimulatory
eﬀect on β-oxidation, a switch occurs from glucose to
FA as the primary fuel source. PPARα also impacts on
the balance between glycogen synthesis and glycogenolysis.
Although PPARα activation is associated with a reduction in
glycogen stores, it remains controversial how this is precisely
established.
When considering all published data as a whole, it is
striking that experiments using PPARα ligands do not lead
tothesameconclusionsasthosewithPPARαknockoutmice.
In these mice, however, a whole new metabolic homeostasis
may be installed which hampers distinction between direct
andindirecteﬀectsoftheabsenceofthistranscriptionfactor.
Similar remarks have to be made when organisms are treated
for long periods with synthetic agonists. Other cautionary
notes are that expression levels of metabolic enzymes are
not always predictive of pathway ﬂuxes, and that there is
only partial overlap of genes upregulated by PPARα during
fasting and genes upregulated by synthetic PPARα agonists
[6, 9]. Therefore, the most reliable system to judge the role
of PPARα in carbohydrate metabolism is probably an acute
activation of the transcription factor using physiological
PPARα ligands.
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